Characterization of W-Beijing isolates of Mycobacterium tuberculosis from the Western Cape

Vaccine

Volumn 31, Issue 50, 2013, Pages 5934-5939

  Shanley, Crystal A ^a   Streicher, Elizma M ^b   Warren, Robin M ^b   Victor, Thomas C ^b   Orme, Ian M ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

BCG vaccination; Clinical strains; Guinea pig; Tuberculosis

Indexed keywords

BCG VACCINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; BACTERIUM ISOLATE; BCG VACCINATION; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DOSE RESPONSE; EXPERIMENTAL GUINEA PIG; FEMALE; GRANULOMATOUS INFLAMMATION; LUNG INJURY; LUNG LOBE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SOUTH AFRICA;

BCG VACCINATION; CLINICAL STRAINS; GUINEA PIG; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BCG VACCINE; DISEASE MODELS, ANIMAL; DNA-DIRECTED RNA POLYMERASES; FEMALE; GUINEA PIGS; HUMANS; LUNG; MICROBIAL SENSITIVITY TESTS; MOLECULAR TYPING; MYCOBACTERIUM TUBERCULOSIS; SOUTH AFRICA; TUBERCULOSIS;

EID: 84887606833     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.044     Document Type: Article

References (27)

1. Dye C., Glaziou P., Floyd K., Raviglione M. Prospects for tuberculosis elimination. Annual Review of Public Health 2013, 34:271-286.
2. McShane H., Jacobs W.R., Fine P.E., Reed S.G., McMurray D.N., Behr M., et al. BCG: Myths, realities, and the need for alternative vaccine strategies. Tuberculosis (Edinburgh, Scotland) 2012, 92:283-288.
3. Smith K.C., Orme I.M., Starke J. The BCG Vaccine. Vaccines 2012, WB Saunders. 6th ed. S. Plotkin, W. Orenstein, P. Offit (Eds.).
4. Raviglione M.C., Gupta R., Dye C.M., Espinal M.A. The burden of drug-resistant tuberculosis and mechanisms for its control. Annals of the New York Academy of Sciences 2001, 953(December):88-97.
5. Raviglione M.C., Smith I.M. XDR tuberculosis - implications for global public health. New England Journal of Medicine 2007, 356:656-659.
6. Dye C., Williams B.G. Slow elimination of multidrug-resistant tuberculosis. Science Tanslational Medicine 2009, 1:3ra8.
7. Kaufmann S.H., Gengenbacher M. Recombinant live vaccine candidates against tuberculosis. Current Opinion in Biotechnology 2012, 23:900-907.
8. McShane H. Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philosophical Transactions of the Royal Society of London 2011, 366:2782-2789.
9. Ottenhoff T.H., Kaufmann S.H. Vaccines against tuberculosis: where are we and where do we need to go?. PLoS Pathogens 2012, 8:e1002607.
10. Palanisamy G.S., DuTeau N., Eisenach K.D., Cave D.M., Theus S.A., Kreiswirth B.N., et al. Clinical strains of Mycobacterium tuberculosis display a wide range of virulence in guinea pigs. Tuberculosis (Edinburgh, Scotland) 2009, 89:203-209.
11. Palanisamy G.S., Smith E.E., Shanley C.A., Ordway D.J., Orme I.M., Basaraba R.J. Disseminated disease severity as a measure of virulence of Mycobacterium tuberculosis in the guinea pig model. Tuberculosis (Edinburgh, Scotland) 2008, 88:295-306.
12. Ordway D.J., Shang S., Henao-Tamayo M., Obregon-Henao A., Nold L., Caraway M., et al. Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells. Clinical and Vaccine Immunology 2011, 18:1527-1535.
13. Shang S., Harton M., Tamayo M.H., Shanley C., Palanisamy G.S., Caraway M., et al. Increased Foxp3 expression in guinea pigs infected with W-Beijing strains of M. tuberculosis. Tuberculosis (Edinburgh, Scotland) 2011, 91:378-385.
14. Tameris M.D., Hatherill M., Landry B.S., Scriba T.J., Snowden M.A., Lockhart S., et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381:1021-1028.
15. Dramowski A., Morsheimer M.M., Jordaan A.M., Victor T.C., Donald P.R., Schaaf H.S. Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa. International Journal of Tuberculosis and Lung Disease 2012, 16:76-81.
16. Johnson R., Warren R.M., van der Spuy G.D., Gey van Pittius N.C., Theron D., Streicher E.M., et al. Drug-resistant tuberculosis epidemic in the Western Cape driven by a virulent Beijing genotype strain. International Journal of Tuberculosis and Lung Disease 2010, 14:119-121.
17. Mukinda F.K., Theron D., van der Spuy G.D., Jacobson K.R., Roscher M., Streicher E.M., et al. Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa. International Journal of Tuberculosis and Lung Disease 2012, 16:196-202.
18. Seddon J.A., Hesseling A.C., Marais B.J., Jordaan A., Victor T., Schaaf H.S. The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa. International Journal of Tuberculosis and Lung Disease 2012, 16:928-933.
19. Strauss O.J., Warren R.M., Jordaan A., Streicher E.M., Hanekom M., Falmer A.A., et al. Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence. Journal of Clinical Microbiology 2008, 46:1514-1516.
20. Victor T.C., Streicher E.M., Kewley C., Jordaan A.M., van der Spuy G.D., Bosman M., et al. Spread of an emerging Mycobacterium tuberculosis drug-resistant strain in the western Cape of South Africa. International Journal of Tuberculosis and Lung Disease 2007, 11:195-201.
21. Kraft S.L., Dailey D., Kovach M., Stasiak K.L., Bennett J., McFarland C.T., et al. Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis. Infection and Immunity 2004, 72:5963-5971.
22. Basaraba R.J., Dailey D.D., McFarland C.T., Shanley C.A., Smith E.E., McMurray D.N., et al. Lymphadenitis as a major element of disease in the guinea pig model of tuberculosis. Tuberculosis (Edinburgh, Scotland) 2006, 86:386-394.
23. Kato-Maeda M., Shanley C.A., Ackart D., Jarlsberg L.G., Shang S., Obregon-Henao A., et al. Beijing sublineages of Mycobacterium tuberculosis differ in pathogenicity in the guinea pig. Clinical and Vaccine Immunololgy 2012, 19:1227-1237.
24. Ordway D., Henao-Tamayo M., Harton M., Palanisamy G., Troudt J., Shanley C., et al. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. Journal of Immunology 2007, 179:522-531.
25. Ordway D., Palanisamy G., Henao-Tamayo M., Smith E.E., Shanley C., Orme I.M., et al. The cellular immune response to Mycobacterium tuberculosis infection in the guinea pig. Journal of Immunology 2007, 179:2532-2541.
26. Orme I.M. The Achilles heel of BCG. Tuberculosis (Edinburgh, Scotland) 2010, 90:329-332.
27. McShane H., Pathan A.A., Sander C.R., Goonetilleke N.P., Fletcher H.A., Hill A.V. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinburgh, Scotland) 2005, 85:47-52.